PKPushpinder Kanda

Pushpinder Kanda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pushpinder Kanda has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Adrian Tsang

    Eye Institute, The Ottawa Hospital, Ottawa, Ontario, Canada

    2 shared publications
  • Arnav Gupta

    Department of Medicine, University of Calgary, Calgary, Canada

    2 shared publications
  • Chloe Gottlieb

    Department of Ophthalmology, The University of Ottawa Eye Institute, Ottawa, Canada

    2 shared publications
  • Deeksha Kundapur

    University of Ottawa, Faculty of Medicine, Department of Ophthalmology, Ottawa, Ontario, Canada

    2 shared publications
  • Jobanpreet Dhillon

    Eye Institute, The Ottawa Hospital, Ottawa, Ontario, Canada

    2 shared publications
  • Bonnie Weston

    University of Ottawa, Faculty of Medicine, Department of Ophthalmology, Ottawa, ON, Canada

    1 shared publication

Latest Publications

  • AGGREGATIBACTER APHROPHILUS AS A RARE CAUSE OF ENDOGENOUS ENDOPHTHALMITIS

    by Pushpinder Kanda, Deeksha Kundapur, Henry Chen, Michael Dollin

    Purpose: To describe a rare case of endogenous endophthalmitis caused by Aggregatibacter aphrophilus (A. aphrophilus) in the context of all previously reported cases of endophthalmitis caused by this organism. Methods: A 59-year-old man with no history of ocular trauma or surgery presented with a red, painful right eye with light perception vision. Examination showed a hypopyon, dense fibrin reaction, and cells in the anterior chamber. B-scan ultrasound showed evidence of vitritis. Broad investigations were initiated for both inflammatory and infectious etiologies. Results: The patient was diagnosed with presumed endogenous bacterial endophthalmitis as the blood cultures were positive for A. aphrophilus and vitreous cultures were negative for growth. The patient was promptly treated with intravitreal and systemic antibiotics and later underwent pars plana vitrectomy. The final visual acuity was 20/50. The patient had a prosthetic aortic valve and careful investigations had ruled out endocarditis. Conclusion: This case emphasizes the importance of early recognition, investigation, and intervention for A. aphrophilus endophthalmitis including the role of therapeutic vitrectomy. While early presentation can mimic ocular inflammatory diseases, infection from underrecognized causative organisms like A. aphrophilus should be ruled out. Systemic and intraocular antibiotics should be started promptly to provide the best visual prognosis.

  • Open Access

    Case report: A severe case of zoledronate-associated diffuse orbital inflammation and uveitis in a patient with metastatic breast cancer

    by Pushpinder Kanda, Isaura Guerrero-Córdova, Jobanpreet Dhillon, Adrian Tsang

    Introduction: Zoledronate is a commonly prescribed medication to maintain bone health; however, a rare side effect includes ocular inflammation. We report a case of simultaneous anterior uveitis and orbital inflammation associated with zoledronate infusion in a patient with metastatic breast cancer. We also performed a literature search to provide an up-to-date summary of cases with zoledronate-associated ocular inflammation.Methods: This is a case report with literature review. Literature search (timeline 2010 to 2023) was performed using PubMed with the search team: (zoledronate) AND (uveitis OR scleritis OR orbital inflammation OR ocular inflammation).Results: A 48-year-old female presented with left eye pain, swelling, and decreased vision 2 days after receiving zoledronic acid infusion. An ophthalmic exam showed non-granulomatous anterior uveitis. CT orbits and ocular ultrasound showed signs of posterior scleritis and orbital inflammation. Ocular inflammation caused by an infection or metastatic cancer was ruled out. The patient was treated with both topical and systemic corticosteroids. Complete resolution of the inflammation occurred after 2.5 weeks.Conclusion: Orbital inflammation and uveitis are an uncommon side effect of zoledronate but needs to be promptly recognized and treated to prevent sight-threatening complications.


  • Mesenchymal stem cell based therapies for uveitis: a systematic review of preclinical studies

    by Pushpinder Kanda, Arnav Gupta, Jobanpreet Dhillon, Deeksha Kundapur, Chloe C. Gottlieb

    Cell therapy has shown promising results for treating uveitis in preclinical studies. As the field continues to grow towards clinical translation, it is important to review and critically appraise existing studies. Herein, we analysed and critically appraised all preclinical studies using cell therapy or cell derived extracellular vesicles (EVs) for uveitis, and provided insight into mechanisms regulating ocular inflammation. We used PubMed, Medline, and Embase to search for preclinical studies examining stem cell therapy (e.g., mesenchymal stem cells [MSC]) and secreted EVs. All included studies were assessed for quality using the SYstematic Review Center for Laboratory animal Experimentation (SYRCLE) checklist. Sixteen preclinical studies from 2011 to 2022 were analysed and included in this review of which 75% (n = 12) focused only on cell therapy, 18.7% (n = 3) studies focused on EVs, and 6.3% (n = 1) study focused on both cells and EVs. MSCs were the most common type of cells used in preclinical studies (n = 15) and EVs were commonly isolated from MSCs (n = 3). Overall, both MSCs and EVs showed improvements in ocular inflammation (seen on fundoscopy/slit lamp and histology) and electroretinogram outcomes. Overall, MSC and MSC-derived EVs shown great potential as therapeutic agents for treating uveitis. Unfortunately, small sample size, risk of selection/performance bias, and lack of standardized cell harvesting or delivery protocols are some factors which limits clinical translation. Large scaled, randomized preclinical studies are required to understand the full potential of MSCs for treating uveitis.


  • Open Access

    Primary meningococcal conjunctivitis in an adult patient

    by Pushpinder Kanda, Sarantos Ioannidis, Wei Sim, Bonnie Weston, Mona Koaik


  • Open Access

    A novel 5-ring multifocal electroretinography stimulus for detecting hydroxychloroquine retinal toxicity

    by Adrian Tsang, Pushpinder Kanda, Chloe Gottlieb, Gianni Virgili, Lynca Kantungane, Stuart Coupland

    Purpose: Multifocal electroretinogram (mfERG) shows great utility as a screening tool to detect early hydroxychloroquine (HCQ) retinopathy, but its widespread use is limited by the lack of accessibility and long test duration. In this study, we evaluated a novel concentric 5-ring mfERG stimulus to provide a simplified and rapid protocol for screening HCQ toxicity. Methods: Patients referred for HCQ retinopathy screening were consented to this observational cross-sectional study. Patients with amblyopia, high refractive error (more than 8 diopters), other retinal diseases precluding appropriate evaluation or history of retinal surgery were excluded. The data were collected from patients undergoing HCQ screening at a single center from July 2019 to March 2020. Patients were tested with the new concentric 5-ring mfERG stimulus, standard 61-hexagon mfERG stimulus, spectral domain optical coherence tomography and automated 10-2 visual fields. For the main outcome, the 5-ring mfERG was compared to 61-hexagon stimulus to determine the time-to-test completion and assess the association between ring (R1–R5) amplitude and ring ratio compared against cumulative dose, dose by real body weight and duration of therapy using Pearson correlation. Results: In total, 52 patients (104 eyes; 5 males and 47 females) were recruited with a mean age of 59 years (range 23–85 years). The 5-ring protocol was markedly quicker to perform (1.3 ± 0.2 min; mean (SD)) compared to the 61-hexagon protocol (5.2 ± 0.6 min), p < 0.0001; n = 10 patients. The new R2/R5 ring ratio showed a moderate correlation with daily dose (r = − 0.640), cumulative dose (r = − 0.581) and duration of therapy (r = − 0.417). Similar correlations were observed with the new R2/R4 ring ratio which were not significantly different from the new R2/R5 correlation coefficients. The new R2/R5 ring ratio demonstrated a stronger correlation with daily (p = 0.002) and cumulative dose (p = 0.0001) compared to the 61-hexagon stimulus. Conclusions: In this exploratory study, our novel 5-ring mfERG protocol significantly shortened data acquisition time while providing comparable results to the standard 61-hexagon stimulus for detecting HCQ-induced electrophysiological changes that are correlated with HCQ dosages and treatment duration. Our protocol has the potential to be more clinically practical by simplifying routine screening.


  • Pathophysiology of central serous chorioretinopathy: a literature review with quality assessment

    by Pushpinder Kanda, Arnav Gupta, Chloe Gottlieb, Rustum Karanjia, Stuart G. Coupland, Manpartap Singh Bal

    The pathogenesis of central serous chorioretinopathy (CSCR), a pachychoroid disease, is poorly understood. While choroid hyperpermeability and retinal pigment epithelium dysfunction are cornerstones for developing CSCR, the mechanisms at the retinal, vascular, retinal pigment epithelium, and cellular level continue to be an enigma. A few preclinical studies and the development of small-sized, poorly controlled clinical trials have resulted in limited insight into the disease mechanism. Effective treatments for CSCR are still lacking as current trials have produced inconsistent results for functional and structural gains. Thus, critically evaluating the literature to explore disease mechanisms and provide an up-to-date understanding of pathophysiology can provide valuable information and avenues to new treatments. In this study, a comprehensive summary of the mechanistic insight into CSCR is presented while highlighting the shortcomings of current literature. The mechanism was divided into seven sub-categories including mechanical obstruction, inflammation, oxidative stress, paracrine factors, autonomic dysfunction, mineralocorticoid receptors activation, and medications. We implemented validated tools like the JBI and CAMARADES to objectively analyze the quality of both clinical and preclinical studies, respectively. Overall, our analysis of the literature showed that no single mechanism was populated with a large number of sufficiently sized and good-quality studies. However, compiling these studies gave hints not only to CSCR pathogenesis but also pachychoroid disease in general while providing suggestions for future exploration.


  • Bioengineered Corneas Entering the Clinical Realm

    by Victor H. Hu, Pushpinder Kanda, Kamal Malhotra, Emilio I. Alarcon, Miguel Gonzalez-Andrades, Matthew Burton, May Griffith